Clinical Trial Update: Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia [Phase 1]

View source ↗

Summary

Phase 1 trial in stable schizophrenia evaluating CY6463 has completed. The update summarizes safety and pharmacokinetics findings from the study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• CY6463

Snippet

Sponsor: Tisento Therapeutics | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED